Maxim Group analyst Naz Rahman reiterated a Buy rating on Agile Therapeutics (AGRX - Research Report) yesterday and set a price target of $1.00. The company's shares closed yesterday at $0.57.According to TipRanks, Rahman is an analyst with an average return of -28.0% and a 25.86% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, 9 Meters Biopharma, and Galmed Pharmaceuticals.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agile Therapeutics with a $3.00 average price target, a 430.97% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-agile-therapeutics-agrx?utm_source=advfn.com&utm_medium=referral
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Agile Therapeutics Charts.
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Agile Therapeutics Charts.